Tests BMS-986454 for safety and drug levels in rheumatoid arthritis
Tests the drug BMS-986454 against placebo in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
Key facts
- Where
- Ahmedabad, Bangalore, Bhubaneswar, Hyderabad, Mysuru, Nagpur, Pune, and Secunderabad, IndiaSee the 9 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with rheumatoid arthritis who did not respond fully to methotrexate treatment.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Rheumatoid arthritis that started after age 18 and meets the 2010 ACR/EULAR classification criteria. At least 1 swollen joint in the hand or wrist. Not severe RA by DAS28-CRP.
- Earlier treatment
- Must have responded only in part to earlier methotrexate (MTX) treatment.
Main reasons for not taking part
- Another significant medical condition that, in the investigator's judgment, would raise the risk of taking part
- Any condition besides RA that makes the study results hard to interpret
- Severe rheumatoid arthritis by DAS28-CRP at screening or Day -1
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07171983, who can take part
Where in India
- Apollo Hospitals AhmedabadAhmedabad, IndiaTaking people
- BangaloreBangalore, IndiaNot yet recruiting
- BhubaneswarBhubaneswar, IndiaNo longer taking part
- HyderabadHyderabad, IndiaNot yet recruiting
- Nizams Institute of Medical SciencesHyderabad, IndiaTaking people
- MysuruMysuru, IndiaNot yet recruiting
- All India Institute of Medical Sciences (AIIMS) - NagpurNagpur, IndiaTaking people
- Life Point Mutispecialty Hospital Pvt. Ltd.Pune, IndiaTaking people
- Krishna Institute of Medical Sciences LimitedSecunderabad, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07171983
- Record updated
- 1 October 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid ArthritisRead full original descriptionShow less
A 2-Part, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986454 in Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid Arthritis
Inclusion: Participants with Rheumatoid Arthritis must have onset after age 18; Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA; Participants must have evidence of swelling in at least 1 joint of the hand or wrist by clinical examination at screening and Day -1; Participants must have been an incomplete responder to prior methotrexate (MTX) treatment.
Exclusion: Participants must not have any significant medical condition, with the exception of Rheumatoid Arthritis (including but not limited to, neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders) that, in the Investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study; Participants must not have any condition aside from RA that confounds the ability to interpret data from the study; Participants must not have severe Rheumatoid Arthritis as assessed by Disease Activity Score 28 c-reactive protein (DAS28-CRP) at screening or Day -1; Other protocol-defined Inclusion/Exclusion criteria apply.